Microbot Medical Inc. $MBOT Shares Purchased by CIBC Private Wealth Group LLC

Key Points

• CIBC Private Wealth Group LLC increased its stake in Microbot Medical by 137.6% in Q3, adding 842,000 shares to hold 1,454,000 shares (about 2.17% of the company) valued at roughly $4.44 million.
• MBOT has a consensus analyst rating of "Moderate Buy" with a consensus target price of $7.50, following recent buy initiations from Roth MKM, HC Wainwright (target $12), and B. Riley.
• The stock opened at $2.54, trades within a one-year range of $1.35–$4.67 and has a market cap of about $170.6 million, with institutional investors owning approximately 16.3% of the shares.

CIBC Private Wealth Group LLC raised its position in Microbot Medical Inc. (NASDAQ:MBOT - Free Report) by 137.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,454,000 shares of the biotechnology company's stock after acquiring an additional 842,000 shares during the quarter. CIBC Private Wealth Group LLC owned approximately 2.17% of Microbot Medical worth $4,435,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cornerstone Advisory LLC purchased a new stake in shares of Microbot Medical in the 3rd quarter valued at approximately $30,000. American Century Companies Inc. purchased a new stake in shares of Microbot Medical during the 2nd quarter worth $32,000. Zacks Investment Management acquired a new position in shares of Microbot Medical during the third quarter worth $33,000. Squarepoint Ops LLC purchased a new position in Microbot Medical in the third quarter valued at $37,000. Finally, Foundations Investment Advisors LLC purchased a new position in Microbot Medical in the third quarter valued at $38,000. Institutional investors and hedge funds own 16.30% of the company's stock.

Analyst Upgrades and Downgrades

MBOT has been the subject of a number of recent analyst reports. Roth Mkm initiated coverage on Microbot Medical in a report on Wednesday, December 3rd. They set a "buy" rating and a $5.50 price target for the company. HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Microbot Medical in a research note on Friday, November 28th. Finally, B. Riley Financial initiated coverage on Microbot Medical in a report on Tuesday, February 10th. They issued a "buy" rating for the company. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Microbot Medical currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.50.

Microbot Medical Stock Performance

NASDAQ MBOT opened at $2.54 on Friday. The firm's fifty day moving average is $2.21 and its two-hundred day moving average is $2.45. Microbot Medical Inc. has a one year low of $1.35 and a one year high of $4.67. The firm has a market cap of $170.59 million, a PE ratio of -5.64 and a beta of 1.22.

About Microbot Medical

Microbot Medical Inc NASDAQ: MBOT is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.